Not yet recruitingNot a drug-phase studyRelapsing and progressiveNCT07434934

What it found

Still running

No result yet.

What was tested

Treatment tested

  • Augmented Reality Exercises

What it measured

Main measures

  • Gait Velocity- single-task (BTS GAITLAB)

    six weeks

    Walking and mobility
  • Gait velocity during dual-task walking (m/s)

    6 weeks

    Thinking and memoryWalking and mobility

Other measures (18)

  • Balance - Berg Balance Scale (BBS)

    Six weeks

    Walking and mobility
  • Activities-specific Balance Confidence (ABC) Scale score (0-100%)

    6 weeks

    Walking and mobility
  • Five Times Sit-to-Stand test time (seconds)

    6 weeks

  • Functional Mobility Scale (FMS) rating

    6 weeks

    Walking and mobility
  • Biodex Balance System stability index (unit per device output)

    6 weeks

    Walking and mobility
  • Daily step count measured by FIBION (steps/day)

    6 weeks

    Physical function
  • Modified Physical Activity Scale (M-PAS) score

    6 weeks

    Physical function
  • Falls Efficacy Scale-International (FES-I) total score

    6 weeks

    Walking and mobility
  • Modified Fatigue Impact Scale (MFIS) total score

    6 weeks

    Fatigue
  • Short Form-36 (SF-36) health-related quality of life score

    6 weeks

    Quality of life (reported by participants)

Who could take part

Relapsing and progressive · 18 and over

Inclusion Criteria: * Neurologist-confirmed diagnosis of MS according to the revised McDonald criteria and PDDS score of ≤6 * Age above 18 years; * Affected by relapsing remitting and secondary progressive MS * Successful completion of Physical Activity Readiness Questionnaire (PAR-Q) * Presence of mild/moderate cognitive impairment (Montreal Cognitive Assessment - MoCA >18) * Ambulatory for indoor and outdoor mobility with or without an assistive device but without physical assistance Exclusion Criteria: * Acute illness or injury that would prevent safe participation in an exercise program * Presence of any other neurological conditions (e.g., stroke), * Presence of severe psychiatric illness other than anxiety or depression * According to the Diagnostic and Statistical Manual of Mental Disorders, 5th -Edition (DSM- V), * Presence of disabling sensory alterations (i.e. auditory and visual disturbances) * Relapse in the 3 months before enrollment * Current engagement in 3 days a week or more of moderate/vigorous exercise

As registered. Criteria can change, so ask the trial team or your neurologist.

Contact details on the registry

About this trial

In the sponsor's words

Multiple Sclerosis (MS) is the most common NDD affecting young people worldwide. MS can seriously affect quality of life and hinder daily functional activities. Therefore, living with MS is a daunting task for both patients and their families. With the prediction of an increase in life expectancy, it is also expected that MS will pose major challenges to healthcare providers in the UAE and globally in terms of its clinical management and financial implications. This proposed project aims to develop structured AR scenarios that integrate dual-tasking exercises commonly used in MS physiotherapy, specifically designed to meet the needs of PwMS. The primary goal is to evaluate the feasibility, acceptability, and potential benefits of these AR scenarios as a rehabilitation tool for PwMS.

Loading reviews and guidelines…

History

    1. Started

      Aug 2026

    2. Main results due

      Mar 2028

    3. Finished

      Sept 2028

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error